mdlinx mdlinx

Rheumatology - Rheumatoid Arthritis News & Articles

What you'll find here at MDLinx Rheumatology: The top rheumatology clinical articles of the day, plus MDLinx exclusive content

  • Our medical editors bring you the best key learnings published in the top peer-reviewed rheumatology medical journals. You'll find overviews here ranked and organized by topic on rheumatoid arthritis, joint and back pain, osteoarthritis, lupus and autoimmune diseases, osteoporosis and bone fractures. In a matter of minutes, you and all the members of your patient care team can stay current on the literature as it is published.
  • MDLinx exclusive content includes monthly highlights from our physician editor, D. Scott Cunningham, MD, PhD, as well as clinical pearls from The Smartest Internist, The Smartest Family Physician, and The Smartest Pediatrician daily quiz challenges.

Your Unread Messages in Rheumatology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Articles

Latest (6) Full Text Articles (48) Focus on Osteoporosis
Ranked, sorted, and summarized by MDLinx editors from the latest literature
Topics:

361 Interaction between oxidative stress and smoking is associated with an increased risk of rheumatoid arthritis: a case-control study Rheumatology, February 21, 2013    Clinical Article

362 Association between -871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients Rheumatology, February 21, 2013    Review Article

363 IL-17-mediated Bcl-2 expression regulates survival of fibroblast like synoviocytes in rheumatoid arthritis through STAT3 activation Arthritis Research & Therapy, February 21, 2013    Review Article

364 Efficacy and safety of leflunomide in DMARD-naive patients with early rheumatoid arthritis: comparison of a loading and a fixed-dose regimen Rheumatology, February 20, 2013    Clinical Article

365 Characteristics of Sjogrens syndrome in rheumatoid arthritis Rheumatology, February 20, 2013    Clinical Guideline

366 Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study Rheumatology, February 19, 2013    Clinical Article

367 Quantitative and Semiquantitative Bone Erosion Assessment on High-resolution Peripheral Quantitative Computed Tomography in Rheumatoid Arthritis The Journal of Rheumatology, February 19, 2013    Review Article

368 Macrophage migration inhibitory factor (MIF): Genetic evidence for participation in early onset and early stage rheumatoid arthritis Cytokine, February 19, 2013    Review Article

369 Influence of interleukin-4 gene polymorphisms and interleukin-4 serum level on susceptibility and severity of rheumatoid arthritis in Egyptian population Cytokine, February 19, 2013    Review Article

370 Rheumatoid and pyrophosphate arthritis synovial fibroblasts induce osteoclastogenesis independently of RANKL, TNF and IL-6 Journal of Autoimmunity , February 19, 2013    Review Article

371 Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure Clinical Rheumatology, February 18, 2013    Clinical Article

372 Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial Rheumatology, February 18, 2013    Clinical Article

373 Efficacy of the switch to modified-release prednisone in rheumatoid arthritis patients treated with standard glucocorticoids Clinical and Experimental Rheumatology Online, February 18, 2013    Clinical Article

374 Postpublication validation of the 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: where do we stand Current Opinion in Rheumatology, February 18, 2013    Clinical Guideline

375 The temporal relationship between depression and rheumatoid arthritis disease activity, treatment persistence and response: a systematic review Rheumatology, February 18, 2013    Evidence Based Medicine    Clinical Article

376 The Role of the Microbiome in Rheumatic Diseases Current Rheumatology Reports, February 18, 2013    Clinical Guideline

377 Positive synovial vascularity in patients with low disease activity indicates smouldering inflammation leading to joint damage in rheumatoid arthritis: time-integrated joint inflammation estimated by synovial vascularity in each finger joint Rheumatology, February 18, 2013    Review Article

378 Similar clinical outcomes in rheumatoid arthritis with more versus less expensive treatment strategies. Observational data from two rheumatology clinics Clinical and Experimental Rheumatology Online, February 18, 2013    Clinical Guideline

379 Gender Differences in Latin-American Patients With Rheumatoid Arthritis Gender Medicine, February 18, 2013    Evidence Based Medicine

380 Lessons to be learned from periodontitis Current Opinion in Rheumatology, February 18, 2013    Review Article

50 available pages First Previous 19 20 21 22 23 24 25 26 27 28 Next Last

Clinical Pearls in Rheumatology

Highlights in Rheumatology

ACPA correlate with disease progression in JIA

In a study involving 74 patients with juvenile idiopathic arthritis (JIA), 26 patients had detectable anti-citrullinated protein antibodies (ACPA). The ACPA titers correlated with disease progression at baseline and after a median follow-up of 11.5 months. In addition to predicting disease severity and progression, the authors concluded that ACPA were superior to IgM-RF in diagnosing JIA.

Read the article summary

Predicting cardiovascular mortality in SLE

In a study involving 208 patients with SLE followed for 12 years, 42 deaths occurred, 48% of which were considered to be cardiovascular mortalities. Age, increased cystatin C levels, and arterial disease were predictive of all-cause mortality. Cigarette smoking and increased sVCAM-1, hsCRP, abeta2GP1, and aPL antibody levels were predictive of cardiovascular mortality.

Read the article summary

Anti-apoA-1 antibodies predict cardiovascular disease in RA patients

In a study conducted at the University of Geneva involving 118 patients with rheumatoid arthritis, but without cardiovascular disease at baseline, the 10-year Framingham cardiovascular risk score (FRS) was improved with the inclusion of the anti-apoA-1 antibody titer. The median follow-up was 9 years and the incidence of cardiovascular disease was 16%. Other biomarkers, including the NT-proBNP, oxLDL, CRP, and RF levels and the anti-citrullinated peptide antibody titer, did not improve the FRS.

Read the article summary

Get reports via email to claim your reading activity at MDLinx as Category 2 CME (It takes less than a minute)

Most Popular Rheumatology Articles

Last month's top read Top Articles of 2012

Indexed Journals in Rheumatology: Arthritis & Rheumatism, Annals of Rheumatic Diseases, Journal of Rheumatologymore

Other Topics in Rheumatology

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow Us
Facebook

Receive free subspecialty
"5-minute updates" via email

Sign up!

Send the E-mail Newsletter to a Colleague


Send

Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More

Close